-
Sector Analysis
Epilepsy: Epidemiology Report and Forecast to 2035
Why Does Epilepsy Epidemiology Matter? Epilepsy is one of the most widespread neurological disorders globally, characterized by recurrent, unpredictable seizures caused by abnormal electrical activity in the brain. Understanding the size and composition of the diagnosed patient population is critical for assessing future healthcare and treatment needs. In the seven major markets (7MM), active diagnosed prevalent cases of epilepsy are forecast to increase from 6.2 million in 2025 to 6.5 million in 2035, representing an annual growth rate (AGR) of...
-
Product Insights
Cerebral Palsy: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Cerebral Palsy - Global Clinical Trials Review, 2026" provides an overview of Cerebral Palsy Clinical trials scenario. This report provides top line data relating to the clinical trials on Cerebral Palsy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Alzheimer's Disease: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Alzheimer's Disease - Global Clinical Trials Review, 2026" provides an overview of Alzheimer's Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Amyotrophic Lateral Sclerosis: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Amyotrophic Lateral Sclerosis - Global Clinical Trials Review, 2026" provides an overview of Amyotrophic Lateral Sclerosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Amyotrophic Lateral Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy): Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Global Clinical Trials Review, 2026" provides an overview of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Clinical trials scenario. This report provides top line data relating to the clinical trials on Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7...
-
Product Insights
Huntington Disease - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Huntington Disease - Global Clinical Trials Review, 2026" provides an overview of Huntington Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Huntington Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Parkinson's Disease - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Parkinson's Disease - Global Clinical Trials Review, 2026" provides an overview of Parkinson's Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Parkinson's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Encephalitis - Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Encephalitis - Global Clinical Trials Review, 2025" provides an overview of Encephalitis Clinical trials scenario. This report provides top line data relating to the clinical trials on Encephalitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Insomnia: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2032
Understand the Future of the Insomnia Therapeutics Market The insomnia therapeutics market continues to evolve as treatment innovation, unmet patient needs, and changing prescribing patterns reshape the competitive landscape. This report provides a comprehensive analysis of the insomnia market across the 7MM, supported by an Excel-based forecast model covering the period from 2022 to 2032. Z-drugs remain the most common first-line treatment across the US and 5EU markets, while the current pipeline remains limited but diverse, featuring products with varying...
-
Sector Analysis
Barriers for Leqembi and Kisunla in Seeking Reimbursement for Treating Alzheimer's Disease
GlobalData analyses of global regulatory and reimbursement progress indicate that the commercial launches of Leqembi (lecanemab) and Kisunla (donanemab) create a high-stakes test of whether disease-modifying therapies with contested long-term clinical value and safety concerns can nonetheless achieve market access in major markets.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.